- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Quiz
Article
Dermatology Times Spot Test: May 3, 2025
Author(s):
Key Takeaways
- Recent updates in melanoma staging and management of regional lymph nodes are highlighted, reflecting evidence-based changes in clinical guidelines.
- The efficacy of combined BRAF and MEK inhibition is compared to BRAF inhibition alone, showing significant advancements in melanoma treatment.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Dermatology Times presents: Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology.
This week, we’ll focus on skin cancer updates and research in recognition of Melanoma Awareness Month.
Do you have a set of quiz questions to share? Contact editor Emma Andrus at eandrus@mjhlifesciences.com to contribute!
Which histologic subtype of melanoma has the highest risk of sentinel lymph node metastasis, and what clinical feature most strongly predicts that risk?
Which targeted therapy combination is currently FDA-approved for treatment of unresectable or metastatic BRAF V600-mutant melanoma and has demonstrated improved overall survival in phase 3 trials?
What is the current recommendation regarding total body skin examinations for melanoma screening in asymptomatic adults according to the US Preventive Services Task Force?
References
- Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492. doi:10.3322/caac.21409
- Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(4):399-413. doi:10.1200/JCO.2017.75.7724
- Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877-1888. doi:10.1056/NEJMoa1406037
- Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603-615. doi:10.1016/S1470-2045(18)30142-6
- Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-1876. doi:10.1056/NEJMoa1408868
- US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for skin cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(4):429-435. doi:10.1001/jama.2016.8465
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
